RxDoctor Payments Data

Melissa Hakes

Family · Flagstaff, AZNPI 1659149847

Payments from drug & device makers

$1,953in general payments, 2019–2025

Across 67 payments — averaging $29.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$398
  • Madrigal Pharmaceuticals$293
  • AbbVie$233
  • Johnson & Johnson$186
  • Lilly USA, LLC$112
  • Pfizer$109
  • plus $622 from 13 others

What the payments were for

  • Food & beverage$1,953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,953 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$52,994
Medicare patients
308
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$96,932
LinzessLinaclotide21$16,456
Pantoprazole Sodium175$2,315
Omeprazole117$1,394
Colestipol Hcl42$1,304
Cholestyramine LightCholestyramine16$1,072
Lansoprazole16$720
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$449
Famotidine23$351
Dicyclomine Hcl17$220
Sucralfate15$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$233$16,45621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →